The leaves of Murraya koenigii Spreng. also furnish this crystalline alkaloid
which is dextrorotatory with [α]D + 52° (CHCI3). The ultraviolet spectrum
exhibits several absorption maxima occurring at 227, 288,300,315,328,343
and 357 mil. It furnishes a crystalline picrate as pale yellow needles, m.p. 142°C
and on catalytic reduction gives the dihydro derivative, m.p. 101°C and finally
the tetrahydro compound, m.p. 108°C. Spectroscopic and chemical data support
the structure given above.
Mahanimbine is an orally active alkaloid from Murraya koenigii. Mahanimbine inhibits progression of high-fat diet (HFD)-induced metabolic complications in mice[1].
ChEBI: Mahanimbine is a member of carbazoles.
Mahanimbine (2-4 mg/kg; p.o.; daily for 12 weeks) prevents HFD-induced weight gain in mice (male and female)[1].
Mahanimbine prevented HFD-induced hyperlipidemia and fat accumulation in adipose tissue and liver along with the restricted progression of systemic inflammation and oxidative stress[1].
Mahanimbine treatment improves glucose clearance and upregulates the expression of insulin responsive genes in liver and adipose tissue[1].
| Animal Model: | Swiss albino mice (7-8 weeks old, both sex)[1] |
| Dosage: | HFD+LD (2 mg/kg of body weight of mahanimbine), HFD+HD (4 mg/kg of body weight of mahanimbine); |
| Administration: | Oral suspension; daily for 12 weeks |
| Result: | Male HFD+LD and HFD+HD groups showed 51.70±6 3.59% and 47.37±3.73% weight gain, respectively, as compared with 71.02±6 6.04% in HFD fed mice whereas female HFD+LD and HFD+HD groups showed 24.31±1.68% and 25.10±2.61% weight gain as compared with HFD group with 36.69±3.60% of weight gain.
|
Chakraborty, Das, Bose., Sci. Cult. (Calcutta), 32, 83 (1966)
Structure:
Narasimhan, Paradkar, Chitguppi., Tetrahedron Lett., 5501 (1968)
